Markman M
The Cleveland Clinic Cancer Center, The Cleveland Clinic Foundation, OH 44195, USA.
Semin Oncol. 1996 Jun;23(3 Suppl 6):47-9.
Ifosfamide has been assessed in the treatment of ovarian cancer for more than two decades. The drug possesses well-documented but modest activity (10% to 15% range) in women with platinum/alkylating agent-resistant ovarian cancer. A potentially important ongoing clinical trial is attempting to define the level of activity of ifosfamide administered in the salvage setting to patients with advanced ovarian cancer who have been previously treated with a platinum drug plus paclitaxel but not an alkylating agent.
异环磷酰胺用于治疗卵巢癌已有二十多年。该药物在铂类/烷化剂耐药的卵巢癌女性患者中具有充分记录但活性一般（10%至15%范围）。一项正在进行的潜在重要临床试验正试图确定在挽救治疗中给予先前接受过铂类药物加紫杉醇但未接受过烷化剂治疗的晚期卵巢癌患者的异环磷酰胺的活性水平。
